Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsClinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesComparison of human hepatoma HepaRG cells with human and rat hepatocytes in uptake transport assays in order to predict a risk of drug induced hepatotoxicityMembrane transporters in drug developmentIntegration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugsOrganic anion transporting polypeptide 1B3 can form homo- and hetero-oligomersDevelopment of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3.Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.Treating pulmonary arterial hypertension: current treatments and future prospectsPharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsInvestigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Impact of OATP transporters on pharmacokinetics.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers.Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorFunctional characterization of liver enhancers that regulate drug-associated transporters.ABC transporter-dependent brain uptake of the 5-HT1B receptor radioligand [ (11)C]AZ10419369: a comparative PET study in mouse, rat, and guinea pigOrganic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifeneTargeted drug delivery to treat pain and cerebral hypoxiaOptimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaBosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Association of CYP2C9*2 with bosentan-induced liver injury.Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.Role of the bile salt export pump, BSEP, in acquired forms of cholestasis.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives.Efflux and uptake transporters as determinants of statin response.Bosentan for the treatment of adult pulmonary hypertension.Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Transporter-mediated drug-drug interactions.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.
P2860
Q26786582-94601714-C218-45AF-9BBC-1DA24DE8E6AEQ26851546-EF9D9553-62B8-4B57-B95C-DCA988467A56Q27001267-959AF3CF-3CCD-447C-96F5-ABC9D587FA96Q28487995-8C2B0763-63AB-4BEF-B7BF-DD8A598D83A5Q29616802-DF9B5796-A945-49A4-B003-FEC5C90F5FD9Q33460512-3FB6B180-640C-4555-92D5-DBDFA32F63FAQ33655897-E7BC04CD-2977-41C7-8582-EF8B28AE56B1Q33714593-EA18C31E-4552-4164-A85E-FC66202C97BAQ33801128-3AB16C12-9FF4-4203-927E-395B6FEF84F9Q33828993-E5A6739D-3283-4846-BC60-089457A9685CQ33829256-969F009B-6FCD-4CEC-A8EF-3B57B0189A96Q34094825-BB71E859-31B3-4CA7-AB7E-5BCC4FC6143FQ34242199-5C916D86-9282-4366-B3DC-A69FCE38FE15Q34318473-41DEB381-39BE-4361-833E-F0FF5B2BCBD4Q34344390-B09359BF-551C-407B-82EA-9CFFC4D122AFQ34570893-C68CF028-3E18-4B32-B41E-84AD13C20BB9Q34612244-48624D81-BECF-4A66-9799-192D95BAA45FQ34969837-716C0F44-5632-4966-959B-00A6AEEEE1E1Q35080119-5BE0D6D7-C030-4FA4-B180-55609F8514A1Q35290066-69708D02-C0C0-4D00-9DEE-2A27F9F6C5B7Q35583006-006E7488-EB8D-4F0E-9407-E7CFAAE87983Q35675506-83189C3B-F2E9-4C61-8379-5725E45BAFE7Q36334805-CB4EB267-9BC0-47BC-8D95-BFBB828611D6Q36591611-13AEB27B-B205-42D0-9F76-0B16438A7FBBQ37019838-2F1BD5D3-1563-4877-8B67-CBB2C241454BQ37253554-C4C5FE6C-EF8B-400A-A40E-35A067A54C05Q37302470-AD3C5E56-B36B-4DAC-A835-4FA46F3AFC69Q37325319-7E0066FC-7979-4346-BA03-6992B24562A4Q37403190-F9E22E05-4F80-4BAB-A1F6-CF704DD460F9Q37492042-CF24A893-288D-417D-8365-3E67CB8DAA58Q37534587-BDD3AFE8-F0C9-48F6-874C-784499F7C100Q37661069-E0249F4E-6890-4D13-B3D0-9CC7EB18DF1CQ37680968-82C606F1-8053-4B65-8DB1-C3AFA7ED3604Q37709367-319493F2-0680-4F70-BA1B-C73ED321BF73Q37724381-BCBE0C36-7EF6-4F3B-8F1D-998BCEE3322AQ37822722-EE80C593-54DA-4C6D-961D-F47E8B458DC0Q37841614-FF008BE2-CD29-47BD-BFEA-EC726645DC8EQ37905033-C7EB8175-3132-477B-BE9F-293FF175B47AQ37955160-49A4CEC9-354E-4A0A-AB4D-7A4DB432B309Q37960129-3B0117E9-CE80-4F31-B939-45D3F798B1C7
P2860
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@ast
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@en
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@nl
type
label
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@ast
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@en
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@nl
prefLabel
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@ast
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@en
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@nl
P2093
P356
P1476
Bosentan is a substrate of hum ...... A, rifampicin, and sildenafil.
@en
P2093
Alexander Treiber
Bruno Stieger
Ralph Schneiter
Stephanie Häusler
P304
P356
10.1124/DMD.106.013615
P577
2007-05-11T00:00:00Z